Marker Therapeutics - Next-Generation T-Cell-Based Immunotherapies

Marker Therapeutics - Next-Generation T-Cell-Based Immunotherapies

Marker Therapeutics to spend $12 Million on 57,310 Square Foot expansion in Houston.Подробнее

Marker Therapeutics to spend $12 Million on 57,310 Square Foot expansion in Houston.

Marker Therapeutics' adds cell and gene therapy manufacturing to immunotherapy platformПодробнее

Marker Therapeutics' adds cell and gene therapy manufacturing to immunotherapy platform

Next-generation dendritic cell–based vaccines [WEBINAR]Подробнее

Next-generation dendritic cell–based vaccines [WEBINAR]

Next-generation dendritic cell-based vaccinesПодробнее

Next-generation dendritic cell-based vaccines

Marker Therapeutics, Inc. @ 5th Annual IOBDLI ForumПодробнее

Marker Therapeutics, Inc. @ 5th Annual IOBDLI Forum

Актуальное